Increase funding and support for vaccine development and deployment to address current and future pandemic threats.
Pandemics
Pandemics Risk
Assessment for this date
Today's pandemic risk is moderate due to high flu activity, ongoing avian flu outbreaks, and challenges in vaccine deployment and public health responsiveness.
March 10, 2026
Trend
Viewing the record for March 10, 2026 within the full trend.
Risk Drivers
What is pushing the current reading.
The current pandemic risk is elevated by several factors: persistent high flu activity with multiple pediatric deaths, ongoing avian flu outbreaks in both humans and animals, and significant challenges in vaccine deployment and public health responsiveness. The flu season remains severe, with multiple reports of pediatric deaths and high activity levels, indicating a strong spread potential. Avian flu continues to spread in various regions, including new human cases, which raises concerns about zoonotic transmission. Additionally, funding cuts for RNA vaccines and stalled NIH funds threaten long-term vaccine development and public health preparedness. These factors, combined with misinformation and vaccine hesitancy, contribute to a moderate risk level.
Risk Reduction Actions
Priority actions generated from the current analysis.
Enhance surveillance and reporting systems for flu and avian flu to better track and respond to outbreaks.
Promote flu vaccination and educate the public on the importance of timely vaccinations to reduce infection rates.
Work on community outreach programs to combat misinformation and improve vaccine uptake.
Continue studies on zoonotic diseases to understand transmission dynamics and develop effective interventions.
Sources Monitored
Visible feeds used in this category's nightly run.
Selected Articles
Supporting articles referenced in the latest score.
- CDC reports 11 more pediatric flu deaths
- Babies with COVID-19 develop more serious disease than those with RSV, US data reveal
- RNA vaccine funding cuts threaten decades of scientific progress
- European regulators recommend approval of combined mRNA vaccine for flu and COVID
- Cambodia confirms its first human case of H5N1 avian flu this year
- 3 new human avian flu cases reported in China
- RNA vaccine funding cuts threaten decades of scientific progress